USNA Stock Price, USANA Health Sciences Quote, Chart

Market Summary

USD48.95+0.43

Market Closed

0.89%

USNA Alerts

2 major insider sales recently.

USNA Stock Price

View Fullscreen

USNA RSI Chart

USNA Valuation

Market Cap

932.5M

Price/Earnings (Trailing)

15.05

Price/Sales (Trailing)

1.04

EV/EBITDA

5.28

Price/Free Cashflow

15.57

USNA Price/Sales (Trailing)

USNA Profitability

EBT Margin

11.22%

Return on Equity

12.39%

Return on Assets

9.84%

Free Cashflow Yield

6.42%

USNA Fundamentals

USNA Revenue

Revenue (TTM)

900.5M

Rev. Growth (Yr)

-8.28%

Rev. Growth (Qtr)

3.04%

USNA Earnings

Earnings (TTM)

61.9M

Earnings Growth (Yr)

-10.04%

Earnings Growth (Qtr)

-1.37%

Breaking Down USNA Revenue

Last 7 days

4.8%

Last 30 days

13.8%

Last 90 days

-0.9%

Trailing 12 Months

-23.2%

How does USNA drawdown profile look like?

USNA Financial Health

Current Ratio

3.74

USNA Investor Care

Buy Backs (1Y)

1.28%

Diluted EPS (TTM)

3.21

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	900.5M	0	0	0
2023	974.1M	947.8M	927.9M	921.0M
2022	1.2B	1.1B	1.0B	998.6M
2021	1.2B	1.3B	1.2B	1.2B
2020	1.1B	1.1B	1.1B	1.1B
2019	1.2B	1.1B	1.1B	1.1B
2018	1.1B	1.1B	1.2B	1.2B
2017	1.0B	1.0B	1.0B	1.0B
2016	939.6M	964.8M	985.8M	1.0B
2015	827.4M	872.4M	913.8M	918.5M
2014	731.5M	730.6M	748.9M	790.5M
2013	663.7M	691.9M	700.4M	718.2M
2012	592.5M	604.5M	626.1M	648.7M
2011	542.1M	565.0M	573.5M	581.9M
2010	0	463.8M	490.7M	517.6M
2009	0	0	0	436.9M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of USANA Health Sciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 07, 2024	fuller gilbert a	sold	-21,848	44.589	-490	-
May 07, 2024	iiekking g doug	sold	-232,677	44.7627	-5,198	chief financial officer
May 02, 2024	macuga daniel a.	sold	-178,717	47.1424	-3,791	chief communications officer
Apr 24, 2024	pelosi peggie	acquired	-	-	490	-
Apr 24, 2024	wood timothy e	acquired	-	-	490	-
Apr 24, 2024	ding xia	sold (taxes)	-5,375	43.7	-123	-
Apr 24, 2024	fuller gilbert a	acquired	-	-	490	-
Apr 24, 2024	winssinger frederic j	acquired	-	-	490	-
Apr 24, 2024	nixon j scott	acquired	-	-	490	-

Which funds bought or sold USNA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-5.96	-97,448	556,150	-%
May 16, 2024	JANE STREET GROUP, LLC	new	-	666,292	666,292	-%
May 16, 2024	COMERICA BANK	reduced	-10.22	-51,457	222,760	-%
May 16, 2024	Pineridge Advisors LLC	sold off	-100	-1,072	-	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	reduced	-13.23	-452,630	1,653,850	-%
May 15, 2024	Centiva Capital, LP	new	-	200,984	200,984	-%
May 15, 2024	Core Wealth Advisors, Inc.	unchanged	-	-1,020	9,700	-%
May 15, 2024	BOKF, NA	added	274	93,233	132,897	-%
May 15, 2024	HSBC HOLDINGS PLC	added	10.09	-3,437	342,362	-%
May 15, 2024	Point72 Asia (Singapore) Pte. Ltd.	new	-	40,413	40,413	0.01%

Are Funds Buying or Selling USNA?

Are funds buying USNA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own USNA

No. of Funds

USNA Alerts

2 major insider sales recently.

Unveiling USANA Health Sciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	renaissance technologies llc	6.27%	1,198,697	SC 13G/A
Feb 13, 2024	vanguard group inc	8.27%	1,582,742	SC 13G/A
Jan 24, 2024	blackrock inc.	9.6%	1,836,679	SC 13G/A
Feb 13, 2023	renaissance technologies llc	6.38%	1,224,997	SC 13G/A
Feb 09, 2023	vanguard group inc	7.99%	1,534,910	SC 13G/A
Jan 06, 2023	blackrock inc.	10.2%	1,963,866	SC 13G/A
Feb 11, 2022	renaissance technologies llc	7.48%	1,456,097	SC 13G/A
Feb 10, 2022	vanguard group inc	7.70%	1,498,731	SC 13G/A
Feb 01, 2022	blackrock inc.	9.3%	1,802,996	SC 13G/A
Nov 22, 2021	wentz myron w	41.0%	7,985,743	SC 13D/A

Recent SEC filings of USANA Health Sciences Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	144	Notice of Insider Sale Intent
May 07, 2024	144	Notice of Insider Sale Intent
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	8-K	Current Report
May 06, 2024	4/A	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading

Peers (Alternatives to USANA Health Sciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ADM	30.5B	91.7B	1.99%	-15.35%	10.02	0.33	-10.07%	-31.73%
BG	15.0B	61.3B	-2.21%	16.07%	7.7	0.25	-8.91%	30.43%
CAG	14.7B	12.1B	1.62%	-14.16%	15.43	1.21	-0.78%	18.26%
CPB	13.8B	9.3B	7.27%	-12.09%	18.08	1.49	1.02%	-5.78%
ACI	11.9B	79.2B	0.88%	1.68%	9.19	0.15	2.05%	-14.37%
MID-CAP
BRBR	7.5B	1.8B	5.71%	59.23%	39.11	4.06	23.06%	29.48%
FRPT	6.1B	823.2M	20.41%	92.18%	627.36	7.45	30.53%	114.65%
FLO	5.2B	5.1B	4.80%	-15.22%	41.05	1.01	4.66%	-41.11%
CENT	3.0B	3.3B	17.04%	57.25%	20.35	0.91	1.49%	31.18%
CALM	2.8B	2.4B	-3.61%	21.31%	10.29	1.19	-22.17%	-63.60%
SMALL-CAP
ANDE	1.8B	13.6B	-9.19%	34.04%	14.42	0.13	-21.14%	9.65%
BGS	743.1M	2.0B	-11.49%	-26.60%	-6.76	0.37	-5.45%	-247.51%
BYND	467.2M	326.7M	11.98%	-36.95%	-1.4	1.43	-18.66%	-2.70%
ALCO	208.0M	103.1M	2.36%	17.74%	5.21	2.02	56.46%	236.17%
AQB	7.1M	2.6M	5.71%	277.55%	-0.22	2.8	-0.77%	-36.97%

USANA Health Sciences Inc News

Latest updates

USANA Health Sciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	3.0%	228	221	213	238	248	228	233	264	273	267	274	337	308	311	299	259	267	271	261	256	273
Gross Profit	3.3%	185	179	171	195	200	182	187	215	221	215	224	280	250	252	242	211	221	224	213	210	227
Operating Expenses	3.6%	160	155	153	170	173	159	164	186	188	183	183	226	206	199	197	172	182	179	177	178	192
S&GA Expenses	9.6%	64.00	59.00	63.00	68.00	67.00	61.00	66.00	66.00	69.00	69.00	67.00	72.00	72.00	69.00	66.00	61.00	65.00	65.00	66.00	67.00	70.00
EBITDA Margin	0.9%	0.13*	0.13*	0.12*	0.12*	0.12*	0.12*	0.13*	0.14*	0.15*	0.15*	0.17*	0.17*	-	-	-	-	-	-	-	-	-
Interest Expenses	-83.4%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.11	1.00	0.00	0.00	0.00	0.00	0.00	0.00
Income Taxes	7.4%	11.00	10.00	9.00	10.00	10.00	10.00	8.00	10.00	11.00	11.00	13.00	16.00	14.00	15.00	14.00	12.00	13.00	15.00	12.00	11.00	12.00
Earnings Before Taxes	1.9%	27.00	27.00	21.00	27.00	29.00	23.00	23.00	29.00	33.00	32.00	40.00	54.00	44.00	55.00	44.00	40.00	39.00	46.00	36.00	33.00	36.00
EBT Margin	0.9%	0.11*	0.11*	0.11*	0.11*	0.11*	0.11*	0.11*	0.12*	0.14*	0.14*	0.16*	0.16*	-	-	-	-	-	-	-	-	-
Net Income	-1.4%	17.00	17.00	11.00	17.00	18.00	13.00	15.00	19.00	22.00	20.00	27.00	38.00	31.00	40.00	31.00	28.00	27.00	31.00	24.00	21.00	24.00
Net Income Margin	-0.7%	0.07*	0.07*	0.06*	0.07*	0.07*	0.07*	0.07*	0.08*	0.09*	0.10*	0.11*	0.11*	-	-	-	-	-	-	-	-	-
Free Cashflow	-22.6%	14.00	19.00	21.00	6.00	11.00	37.00	26.00	13.00	18.00	22.00	31.00	38.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-0.6%	629	633	601	603	606	597	556	558	573	578	579	591	585	641	578	512	474	517	463	532	552
Current Assets	0.8%	421	418	390	388	396	384	341	342	364	365	368	382	373	425	386	325	287	329	283	349	370
Cash Equivalents	0.2%	331	330	307	300	295	288	247	230	238	240	249	265	257	312	278	227	194	235	183	231	225
Inventory	-1.0%	61.00	61.00	60.00	62.00	64.00	67.00	67.00	84.00	98.00	98.00	96.00	90.00	88.00	90.00	78.00	69.00	61.00	69.00	76.00	88.00	86.00
Net PPE	-1.6%	98.00	100	95.00	96.00	97.00	98.00	95.00	98.00	101	102	101	98.00	99.00	100	99.00	98.00	97.00	95.00	92.00	93.00	92.00
Goodwill	-1.2%	17.00	17.00	17.00	17.00	17.00	17.00	17.00	1.00	18.00	18.00	18.00	17.00	17.00	17.00	17.00	17.00	16.00	17.00	16.00	17.00	17.00
Current Liabilities	-5.2%	113	119	113	114	130	144	126	134	158	161	158	153	151	168	161	140	125	136	130	129	130
Shareholder's Equity	0.6%	500	497	470	469	455	434	411	404	390	395	399	419	403	442	389	349	318	352	314	384	391
Retained Earnings	1.8%	453	445	428	427	410	392	379	364	345	345	350	366	353	383	343	313	285	306	275	328	329
Additional Paid-In Capital	-0.8%	65.00	66.00	62.00	60.00	56.00	56.00	52.00	49.00	46.00	50.00	51.00	54.00	54.00	62.00	59.00	56.00	52.00	59.00	57.00	69.00	69.00
Shares Outstanding	-0.4%	19.00	19.00	19.00	19.00	19.00	19.00	19.00	19.00	19.00	20.00	20.00	21.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	699	-	-	-	1,426	-	-	-	2,052	-	-	-	817	-	-	-	1,040	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-32.0%	17,683	26,023	22,234	9,551	12,833	40,463	29,125	14,613	19,701	24,922	37,488	39,158	19,659	47,915	49,062	32,638	30,786	55,740	50,314	15,158	5,521
Share Based Compensation	0.7%	3,669	3,643	3,670	3,674	3,608	3,516	3,076	3,556	3,183	3,259	3,454	3,845	3,740	3,875	3,528	3,597	3,394	2,857	4,083	4,769	3,832
Cashflow From Investing	44.4%	-4,068	-7,322	-1,454	179	-3,378	-3,282	-3,579	-3,723	-1,786	-3,153	-6,452	-1,494	-3,088	-21,433	-2,732	-1,526	-8,270	-5,105	-1,185	21,275	32,509
Cashflow From Financing	-1915.5%	-11,946	658	-11,641	-55.00	-3,199	-150	-44.00	-10,301	-19,593	-32,445	-46,831	-31,661	-70,475	-472	-43.00	-75.00	-58,852	-305	-92,476	-27,858	-31,413
Buy Backs	-	9,483	-	11,657	-	-	-	-	-	25,382	31,343	49,751	29,701	67,610	-	-	-	57,029	-	92,377	27,623	30,000

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

USNA Income Statement

2024-03-30

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 30, 2024	Apr. 01, 2023
Income Statement [Abstract]
Net sales	$ 227,800	$ 248,360
Cost of sales	43,069	48,519
Gross profit	184,731	199,841
Operating expenses:
Associate incentives	95,758	106,070
Selling, general and administrative	64,300	66,926
Total operating expenses	160,058	172,996
Earnings from operations	24,673	26,845
Other income (expense):
Interest income	2,676	1,775
Interest expense	(52)	(31)
Other, net	(186)	(88)
Other income (expense), net	2,438	1,656
Earnings before income taxes	27,111	28,501
Income taxes	10,574	10,118
Net earnings	$ 16,537	$ 18,383
Earnings per common share
Basic (in dollars per share)	$ 0.86	$ 0.95
Diluted (in dollars per share)	$ 0.86	$ 0.95
Weighted average common shares outstanding
Basic (in shares)	19,174	19,283
Diluted (in shares)	19,302	19,328
Comprehensive income:
Net earnings	$ 16,537	$ 18,383
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	(5,102)	1,654
Tax benefit (expense) related to foreign currency translation adjustment	204	98
Other comprehensive income (loss), net of tax	(4,898)	1,752
Comprehensive income	$ 11,639	$ 20,135

USNA Balance Sheet

2024-03-30

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 30, 2024	Dec. 30, 2023
Current assets
Cash and cash equivalents	$ 328,336	$ 330,420
Inventories	60,870	61,454
Prepaid expenses and other current assets	31,864	25,872
Total current assets	421,070	417,746
Property and equipment, net	98,186	99,814
Goodwill	16,902	17,102
Intangible assets, net	29,105	29,919
Deferred tax assets	11,347	13,284
Other assets	52,665	54,892
Assets, total	629,275	632,757
Current liabilities
Accounts payable	8,266	10,070
Line of credit - short term	1,320	786
Other current liabilities	103,045	107,989
Total current liabilities	112,631	118,845
Deferred tax liabilities	5,113	4,552
Other long-term liabilities	11,543	12,158
Stockholders' equity
Common stock, $0.001 par value; Authorized -- 50,000 shares, issued and outstanding 19,047 as of March 30, 2024 and 19,130 as of December 30, 2023	19	19
Additional paid-in capital	65,111	65,661
Retained earnings	453,451	445,217
Accumulated other comprehensive income (loss)	(18,593)	(13,695)
Total stockholders' equity	499,988	497,202
Liabilities and equity, total	$ 629,275	$ 632,757

About USANA Health Sciences Inc

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.

CEO	Mr. Jim Brown
WEBSITE	usana.com
INDUSTRY	Packaged Foods
EMPLOYEES	1900

USANA Health Sciences Inc Frequently Asked Questions

What is the ticker symbol for USANA Health Sciences Inc? What does USNA stand for in stocks?

USNA is the stock ticker symbol of USANA Health Sciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of USANA Health Sciences Inc (USNA)?

As of Fri May 17 2024, market cap of USANA Health Sciences Inc is 932.53 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of USNA stock?

You can check USNA's fair value in chart for subscribers.

What is the fair value of USNA stock?

You can check USNA's fair value in chart for subscribers. The fair value of USANA Health Sciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of USANA Health Sciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for USNA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is USANA Health Sciences Inc a good stock to buy?

The fair value guage provides a quick view whether USNA is over valued or under valued. Whether USANA Health Sciences Inc is cheap or expensive depends on the assumptions which impact USANA Health Sciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for USNA.

What is USANA Health Sciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, USNA's PE ratio (Price to Earnings) is 15.05 and Price to Sales (PS) ratio is 1.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. USNA PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on USANA Health Sciences Inc's stock?

In the past 10 years, USANA Health Sciences Inc has provided 0.108 (multiply by 100 for percentage) rate of return.